-
公开(公告)号：US11932675B2
公开(公告)日：2024-03-19
申请号：US17067508
申请日：2020-10-09
Applicant: Genentech, Inc. , Xencor, Inc.
Inventor： John Desjarlais , Matthew Bernett , Michael Hedvat , Rajat Varma , Suzanne Schubbert , Christine Bonzon , Rumana Rashid , Juan Diaz , Patrick Holder , Christine Huang
CPC classification number: C07K14/5443 , A61P35/00 , C07K16/2818 , A61K38/00 , C07K2319/30
Abstract: The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.
-
公开(公告)号：US20240294593A1
公开(公告)日：2024-09-05
申请号：US18416464
申请日：2024-01-18
Applicant: Genentech, Inc. , Xencor, Inc.
Inventor： John Desjarlais , Matthew Bernett , Michael Hedvat , Rajat Varma , Suzanne Schubbert , Christine Bonzon , Rumana Rashid , Juan Diaz , Patrick Holder , Christine Huang
CPC classification number: C07K14/5443 , A61P35/00 , C07K16/2818 , A61K38/00 , C07K2319/30
Abstract: The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.
-
公开(公告)号：US20210230243A1
公开(公告)日：2021-07-29
申请号：US17067508
申请日：2020-10-09
Applicant: Genentech, Inc. , Xencor, Inc.
Inventor： John Desjarlais , Matthew Bernett , Michael Hedvat , Rajat Varma , Suzanne Schubbert , Christine Bonzon , Rumana Rashid , Juan Diaz , Patrick Holder , Christine Huang
Abstract: The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.
-
4.发明公开公开(公告)号：US20240026002A1
公开(公告)日：2024-01-25
申请号：US18452395
申请日：2023-08-18
Applicant: Xencor, Inc.
Inventor： Matthew J. Bernett , Gregory Moore , John Desjarlais , Michael Hedvat , Christine Bonzon
CPC classification number: C07K16/2818 , A61P35/00 , A61P37/06 , C07K16/2803 , C07K16/2827 , C07K2317/55 , C07K2317/622 , C07K2317/64 , C07K2317/76 , C07K2317/52 , C07K2317/33 , C07K2317/31 , A61K2039/507
Abstract: The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.
-
公开(公告)号：US11851466B2
公开(公告)日：2023-12-26
申请号：US17062458
申请日：2020-10-02
Applicant: Xencor, Inc.
Inventor： Matthew Bernett , John R. Desjarlais , Rajat Varma , Ke Liu , Rumana Rashid , Nargess Hassanzadeh-Kiabi , Michael Hedvat
CPC classification number: C07K14/5434 , A61P35/00 , C07K16/2818 , C07K16/2827 , A61K2039/505 , C07K2317/622 , C07K2319/30
Abstract: The present invention relates to targeted IL-12 heterodimeric Fc fusion proteins, where the fusion proteins bind to human PD-1 or human PD-L1.
-
Patent Agency Ranking
6.发明授权公开(公告)号：US11377477B2
公开(公告)日：2022-07-05
申请号：US16600236
申请日：2019-10-11
Applicant: Xencor, Inc.
Inventor： Matthew Bernett , John R. Desjarlais , Michael Hedvat , Suzanne Schubbert , Christine Bonzon , Rumana Rashid , Rajat Varma
Abstract: The present invention is directed to novel PD-1 targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein. In some embodiments, the PD-1 targeted IL-15/Rα-Fc fusion proteins are administered to a patient to treat cancer. In some embodiments, the PD-1 targeted IL-15/Rα-Fc fusion proteins are administered in combination with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab. In some embodiments, the PD-1 targeted IL-15/Rα-Fc fusion proteins do not compete with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab for antigen binding.
-
公开(公告)号：US20190263909A1
公开(公告)日：2019-08-29
申请号：US16184895
申请日：2018-11-08
Applicant: Xencor, Inc.
Inventor： Matthew Bernett , Gregory Moore , John Desjarlais , Michael Hedvat , Christine Bonzon , Alex Nisthal
Abstract: The present invention is directed to bispecific, heterodimeric checkpoint antibodies.
-
公开(公告)号：US20250043001A1
公开(公告)日：2025-02-06
申请号：US18605762
申请日：2024-03-14
Applicant: Xencor, Inc.
Inventor： Gregory Moore , Viralkumar Rameshkumar Davra , Dong Hyun Nam , Veronica Gusti Zeng , Michael Hedvat , Jing Qi , Rumana Rashid , Patrick Arpp , Ernesto Delgado , ChaoFang Tan , Heather Preciado Jimenez , Charles G. Bakhit , Juan Diaz
Abstract: Provided herein are novel anti-CD28 x anti-STEAP1 and anti-CD28 x anti-CEACAM5 antibodies and methods of using such antibodies for the treatment of related cancers.
-
公开(公告)号：US20230257466A1
公开(公告)日：2023-08-17
申请号：US18074411
申请日：2022-12-02
Applicant: Xencor, Inc.
Inventor： John R. Desjarlais , Gregory Moore , Michael Hedvat , Juan Diaz , Veronica Gusti Zeng
IPC: C07K16/28
CPC classification number: C07K16/2827 , C07K16/2818 , C07K2317/31 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/56 , C07K2317/622
Abstract: Provided herein are novel anti-CD28×anti-B7H3 (also referred to as “αCD28×αB7H3”) heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers. Subject αCD28×αB7H3 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and targeting to B7H3 on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful for enhancing anti-tumor activity when used in combination with other anti-cancer therapies.
-
10.发明申请公开(公告)号：US20230055445A1
公开(公告)日：2023-02-23
申请号：US17831197
申请日：2022-06-02
Applicant: Xencor, Inc.
Inventor： Matthew Bernett , John R. Desjarlais , Michael Hedvat , Suzanne Schubbert , Christine Bonzon , Rumana Rashid , Rajat Varma
IPC: C07K14/54 , C07K16/28 , A61K39/395 , C12N15/63
Abstract: The present invention is directed to novel PD-1 targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein. In some embodiments, the PD-1 targeted IL-15/Rα-Fc fusion proteins are administered to a patient to treat cancer. In some embodiments, the PD-1 targeted IL-15/Rα-Fc fusion proteins are administered in combination with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab. In some embodiments, the PD-1 targeted IL-15/Rα-Fc fusion proteins do not compete with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab for antigen binding.
-
-
-
-
-
-
-
-
-
Search Results
43
records
(took 0.034 seconds)
